- Home
- BTAI vs AIRG Comparison
BTAI vs AIRG Comparison
Compare BTAI & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | AIRG |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 47.4M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BTAI | AIRG |
|---|---|---|
| Price | $1.60 | $4.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.80 | $6.33 |
| AVG Volume (30 Days) | ★ 463.9K | 33.3K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $752,000.00 | ★ $54,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $441.98 | $16.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $3.00 |
| 52 Week High | $9.26 | $8.47 |
Technical Indicators
Market Signals| Indicator | BTAI | AIRG |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 52.88 |
| Support Level | $1.50 | $3.69 |
| Resistance Level | $1.89 | $4.05 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 13.77 | 90.24 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.